Long-Term Effectiveness of Onabotulinum Toxin-A in a Combined Total Endoscopic Management of Pediatric Vesicoureteral Reflux in Neurogenic Bladder Dysfunction
Toxins · 29.06.2025 · 17 (7) · 330
DOI: 10.3390/toxins17070330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, online erschienen am 29.06.2025. Verfasst von Claudio Paratore und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Urology, Bambino Gesù Children's Hospital, IRCCS, ERN eUROGEN Affiliated Center, Piazza di Sant'Onofrio 4, 00165 Rome, Italy. Hauptthemen laut MEDLINE: Vesico-Ureteral Reflux, Botulinum Toxins, Type A, Urinary Bladder, Neurogenic, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health with Current Research funds.
Abstract (Originalsprache)
Vesicoureteral reflux (VUR) management in children with neurogenic bladder dysfunction (NBD) remains a clinical challenge. Total endoscopic management (TEM), combining intradetrusor Onabotulinum Toxin-A (BTX-A) and subureteric dextranomer/hyaluronic acid (Deflux(R)) injection, offers a minimally invasive alternative. The aim of this retrospective study is to evaluate the long-term effectiveness of TEM. Inclusion criteria: symptomatic II–V grade VUR (also I in bilateral VUR) in NBD children with follow-up ≥12 months. Nineteen patients were enrolled, 24 ureters (grade I–II: 2, grade III–V: 22); 5 patients (20.8%) had bilateral VUR. Mean age at surgery: 7.6 years (1.3–17). No complications were reported. TEM was effective in 11 patients (57.9%), 3/11 requiring a second TEM treatment. VUR resolution appeared in 14 ureters (58.3%), downgrading in 6 (42.9%), persistence in 4 (28.6%). Among non-responders’ patients (8/19, 42.1%), five (26.3%) required bladder augmentation (one combined with ureteral reimplantation), one (5.3%) underwent reimplantation, and two (10.5%) continued conservative management. At bladder biopsy, 11 patients (57.9%) had chronic inflammation, 8 (42.1%) showed fibrosis; no difference in success rate was recorded. All responders required repeated BTX-A injections. Mean follow-up: 3.2 years (range 1–4.7). In selected patients, TEM appears to be a safe and effective strategy, potentially delaying or avoiding major reconstructive surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neuro-Urology, Bambino Gesù Children's Hospital, IRCCS, ERN eUROGEN Affiliated Center, Piazza di Sant'Onofrio 4, 00165 Rome, Italy.
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Sciences, University of Genoa, Via Balbi 5, 16126 Genoa, Italy.
- Department of Urology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy.
ORCID-Profile: Chiara Pellegrino, Noemi Deanesi, Giovanni Mosiello
Förderung
- Italian Ministry of Health with Current Research funds
Zitieren
APA
Paratore, C., Pellegrino, C., Deanesi, N., Pulvirenti, R., Capitanucci, M. L., & Mosiello, G. (2025). Long-Term Effectiveness of Onabotulinum Toxin-A in a Combined Total Endoscopic Management of Pediatric Vesicoureteral Reflux in Neurogenic Bladder Dysfunction. Toxins, 17(7), 330. https://doi.org/10.3390/toxins17070330
Vancouver
Paratore C, Pellegrino C, Deanesi N, Pulvirenti R, Capitanucci ML, Mosiello G. Long-Term Effectiveness of Onabotulinum Toxin-A in a Combined Total Endoscopic Management of Pediatric Vesicoureteral Reflux in Neurogenic Bladder Dysfunction. Toxins. 2025;17(7):330. doi:10.3390/toxins17070330
BibTeX
@article{Paratore2025,
author = {Paratore, Claudio and Pellegrino, Chiara and Deanesi, Noemi and Pulvirenti, Rebecca and Capitanucci, Maria Luisa and Mosiello, Giovanni},
title = {Long-Term Effectiveness of Onabotulinum Toxin-A in a Combined Total Endoscopic Management of Pediatric Vesicoureteral Reflux in Neurogenic Bladder Dysfunction},
journal = {Toxins},
year = {2025},
volume = {17},
number = {7},
pages = {330},
doi = {10.3390/toxins17070330}
}
EUVIMED